IFF — Deck
IFF is a global flavors, fragrances, and biosciences maker. It sells the 1-5% ingredient inside food, drinks, perfumes, detergents, and enzymes, earning margin on proprietary formulations locked into customer core lists.
A deleveraging story — or an asset-sale story running out of assets.
- Bull read. Debt has fallen from $11.4B in 2021 to $6.0B at end-2025. Every additional $1B retired is worth ~$40M in annual after-tax earnings, and management's 3x leverage target sits a year or two out.
- Bear read. 2025's $2.9B of debt paydown is essentially the $2.85B Pharma Solutions sale recycled. Operating free cash flow collapsed to $256M — a 75% compression in four years — and can't fund the next leg alone.
- The fulcrum. Food Ingredients, 30% of revenue at a 13% EBITDA margin, is formally up for sale. The clearing price — $3.0B versus $3.6B — decides whether the story is margin repair or capital-allocation capitulation.
Balance sheet is healing. The cash engine is not — yet.
The 2021 DuPont Nutrition & Biosciences merger loaded $16.4B of goodwill onto the books; four straight years of impairments have written off $3.89B of it. Adjusted EBITDA held at $2.09B in 2025 — resilient through destocking, but still 15% below the 2022 peak despite three stacked productivity programs. Reported losses are largely non-cash goodwill noise; the ask is whether operating cash reaccelerates toward a $500M run-rate in 2026.
Food Ingredients is the clearing price that decides the next chapter.
Before: Frutarom (2018) and DuPont N&B (2021) built a four-segment conglomerate at cyclical prices. Peak operating margin went from 19% to negative. Goodwill ballooned to $16.4B, and two CEOs exited before the integration finished.
Pivot: Pharma Solutions closed to Roquette for up to $2.85B in May 2025. Food Ingredients — 30% of revenue, 13% EBITDA margin, eight points below Taste — was formally launched for sale on the February 11 Q4 call. A clean at-or-above-carrying-value exit lifts consolidated margin 300-400 bps toward Givaudan's.
Today: The market prices the divestiture as when-and-at-what-price, not if. At 1.1x revenue it clears above book; at 0.9x it triggers a fourth consecutive goodwill impairment of $0.8-1.5B.
Directors and the CEO put $19M of their own money into the low.
- Director Paul Fribourg. Bought ~$12.0M on the open market between August 2025 and March 2026 at $63-$75. Continental Grain now holds roughly 1% of IFF.
- CEO Erik Fyrwald. Added $5.8M across six transactions at $65-$80 — on top of the $19M stock package he took to join in February 2024.
- The tape. $20.2M of open-market purchases against $1.1M of sales over the last twelve months. Four other directors and the new General Counsel also bought. This is people who see the numbers first putting real money into a 51% five-year drawdown.
Close call. Wait for the May 6 print before sizing in.
- The case. Oligopoly economics, a credible outside CEO, and 1.2x book on a business that historically ran at 19% operating margins. If Food Ingredients clears above $3.0B and operating FCF reaccelerates toward $500M, the mechanical bridge to a $95 target has a foundation.
- The risk. Four straight years of goodwill impairment; a GLP-1 risk factor that wasn't in the 2023 10-K; organic growth that halved from 6% in 2024 to 2% in 2025. On honest EBITDA, interest coverage is negative and the Altman Z sits at 1.1 — below distress.
- The flip condition. A clean Q1 2026 operating FCF print that annualizes above $500M, paired with organic growth north of 3%. At that point the 1.2x book starts to matter again.
Watchlist to re-rate: Q1 2026 operating FCF (May 6). Food Ingredients clearing price. Form 4 filings — does insider buying continue through Q2 weakness?